Authors‘ reply to the letter to the editor by Fedai et al.: “Long-term safety and efficacy of pegvisomant monotherapy for acromegaly: final data from the full ACROSTUDY cohort”
本文未提供摘要，请点击“查看全文”查看完整内容。